Several studies have shown that ALKBH5 inhibits Bcl2 degradation by reducing m6A modification, thereby regulating cell apoptosis in ovarian cancer, hepatocellular carcinoma and cerebral ischemia-reperfusion injury [17,18,19]. The gene discussed is BCL2; the disease is hepatocellular carcinoma.